Navigation Links
Boehringer Ingelheim's Swiss Branch Improves Sales Reporting and Efficiency with MicroStrategy Software
Date:8/26/2009

MCLEAN, Va., Aug. 26 /PRNewswire-FirstCall/ -- MicroStrategy((R)) Incorporated (Nasdaq: MSTR), a leading worldwide provider of business intelligence (BI) software, today announced that Boehringer Ingelheim (Schweiz) GmbH (named here as Boehringer Switzerland) has selected MicroStrategy to improve its sales reporting and efficiency. Boehringer Switzerland is the Swiss branch of the international pharmaceuticals company Boehringer Ingelheim.

Boehringer Switzerland selected MicroStrategy for reporting and analysis of sales productivity data. With MicroStrategy, sales data can now be supplied more rapidly to field sales and management, which helps the company to streamline operations. With MicroStrategy's flexible, user-friendly reports, individual users can create their own reports and work more efficiently. In addition, the reports give Boehringer Switzerland management greater insights into market data to help them plan sales activity and analyze the productivity of regional sales groups.

As part of its extensive selection process, the Boehringer Switzerland management team defined 10 Key Performance Indicators and asked selected BI providers to create several reports with this information. "MicroStrategy made an excellent impression during our evaluation process. In addition, our team in Australia has already deployed MicroStrategy for reporting and has had positive results," said Mr. Gregor Brunner, Department Manager IT of Boehringer Switzerland.

"MicroStrategy provides greater reporting capabilities than other BI suppliers and is very user-friendly," explained Alexander Herter, Business Analyst at Boehringer Switzerland and Project Manager for the evaluation of the new BI solution. "Data can be supplied rapidly and more clearly with MicroStrategy, and the reports serve as a basis for operational and strategic decisions."

"We are pleased to have the Swiss branch of Boehringer Ingelheim, one of the world's leading pharmaceutical companies, as our new customer," said Sanju Bansal, MicroStrategy's COO.

About Boehringer Switzerland

The Boehringer headquarters is in Ingelheim, Germany and the enterprise Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

About MicroStrategy

Founded in 1989, MicroStrategy is a global leader in business intelligence (BI) technology. MicroStrategy provides integrated reporting, analysis, and monitoring software that helps leading organizations worldwide make better business decisions every day. Companies choose MicroStrategy for its advanced technical capabilities, sophisticated analytics, and superior data and user scalability. More information about MicroStrategy (Nasdaq: MSTR) is available at www.microstrategy.com.

MicroStrategy and MicroStrategy Business Intelligence Platform are either trademarks or registered trademarks of MicroStrategy Incorporated in the United States and certain other countries. Other product and company names mentioned herein may be the trademarks of their respective owners.

    Contact:
    Wende Cover
    MicroStrategy Incorporated
    703-770-1646
    wcover@microstrategy.com


'/>"/>
SOURCE MicroStrategy Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
2. AmeriCares and Boehringer Ingelheim Open New, Expanded Free Clinic to Help Families Hit Hardest by Economic Hardship
3. Boehringer Ingelheim Recognized For Diversity And Inclusion Efforts
4. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
5. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
6. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
7. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
8. Do the Swiss Have the Answer to Americas Health Care Dilemma?
9. EMH Swiss Medical Publisher Ltd. Selects Editorial Manager for Online Peer Review
10. Swissray Awarded US Government Contract
11. Swiss Res Employer Stop Loss Product Offers US Companies Cost Savings for Self-Funded Health Insurance Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: